Needham & Company LLC Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $185.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective decreased by Needham & Company LLC from $187.00 to $185.00 in a research note released on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Thursday, January 22nd. Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, February 8th. UBS Group reduced their price objective on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Finally, TD Cowen upped their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a report on Friday, December 5th. Sixteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.42.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $124.12 on Thursday. The stock has a fifty day moving average price of $140.14 and a two-hundred day moving average price of $140.44. The stock has a market capitalization of $12.46 billion, a price-to-earnings ratio of 26.64, a PEG ratio of 0.58 and a beta of 0.31. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company had revenue of $805.50 million for the quarter, compared to analysts’ expectations of $804.21 million. During the same quarter in the previous year, the firm posted $1.69 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 28.3% on a year-over-year basis. On average, analysts predict that Neurocrine Biosciences will post 4.28 EPS for the current year.

Insider Activity

In other news, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Leslie V. Norwalk sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $152.23, for a total transaction of $761,150.00. Following the transaction, the director directly owned 7,429 shares in the company, valued at $1,130,916.67. The trade was a 40.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 61,966 shares of company stock worth $8,625,166. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NBIX. JPMorgan Chase & Co. boosted its holdings in shares of Neurocrine Biosciences by 59.6% during the second quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock worth $535,659,000 after purchasing an additional 1,590,749 shares during the last quarter. AQR Capital Management LLC increased its stake in Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after purchasing an additional 1,263,633 shares during the last quarter. Norges Bank purchased a new position in Neurocrine Biosciences during the fourth quarter worth about $162,664,000. Los Angeles Capital Management LLC boosted its stake in Neurocrine Biosciences by 19,454.9% in the 2nd quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock worth $93,595,000 after buying an additional 740,842 shares during the last quarter. Finally, UBS Group AG grew its holdings in Neurocrine Biosciences by 169.8% in the 4th quarter. UBS Group AG now owns 983,528 shares of the company’s stock valued at $139,494,000 after buying an additional 618,956 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts reiterated Buy/Outperform ratings and raised some price targets (Citigroup to $204, Bank of America reiterated Buy with a $190 target, Needham nudged to $185), signaling continued confidence in Ingrezza durability and pipeline upside. Analyst moves (Benzinga / TipRanks)
• Positive Sentiment: Q4 revenue grew strongly (~28% YoY to ~$805.5M) and company commentary highlighted Ingrezza sales growth and emerging uptake of pipeline assets — supports longer-term revenue trajectory. Earnings highlights (Yahoo)
• Neutral Sentiment: Deeper analysis pieces discuss growth beyond Ingrezza and portfolio opportunities that could drive medium-term upside but caution that 2026 may be less eventful. Useful for investors assessing longer-horizon thesis. Seeking Alpha: Growth Beyond Ingrezza
• Neutral Sentiment: Full Q4 earnings call transcripts and analyst note compilations are available for investors wanting primary commentary on guidance, expense cadence, and pipeline timelines. Review for detail before trading on headlines. Earnings transcripts & summaries
• Negative Sentiment: EPS missed expectations (Q4 EPS ~$1.88 vs. several consensus figures higher), and management issued cautious 2026 guidance — the combination sparked downside pressure and short-term uncertainty. Zacks: Q4 EPS lag
• Negative Sentiment: Some firms trimmed price targets or downgraded to Market Perform (BMO to $140; RBC and Wells Fargo trimmed targets though keeping Outperform/Overweight designations), reflecting more cautious near-term outlooks. Price target changes (Benzinga)
• Negative Sentiment: Market commentary highlights the stock’s sharp pullback after guidance and the EPS miss — articles explaining recent 8%+ decline underscore the sentiment risk if sales or cost pressures persist. AAII: Why NBIX is down

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.